A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Public ClinicalTrials.gov record NCT07265674. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Open-label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients With Previously Treated Advanced Biliary Tract Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to 1) select a dose regimen for continued development and 2) evaluate nanvuranlat versus Physicians Best Choice (PBC) (FOLFOX, FOLFIRI, or Best Supportive Care (BSC)) in participants aged 18 years and over with BTC. Participants enrolling in Part A the trial will be randomly assigned to receive 1 of 3 nanvuranlat dose regimens or PBC. In Part B, participants will be randomly assigned to receive nanvuranlat or PBC. Participants will receive treatment every 2 weeks for as long as they do not experience safety issues, or their cancer gets worse, and the study doctor feels they should stop treatment. Health measurements including physical examinations, vital signs, ECGs, and safety laboratory tests will be performed to monitor safety, and tumor imaging will be performed to monitor cancer response to treatment. Other exploratory makers will be measured to better understand how nanvuranlat works.
Study identification
- NCT ID
- NCT07265674
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 480 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 11, 2026 (Actual)
- Primary completion
- Oct 2027 (Estimated)
- Completion
- Oct 2027 (Estimated)
- Last update posted
- Sep 29, 2026
2026 – 2027
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope (Site 107) | Duarte | California | 91010 | Recruiting |
| University of California at Irvine (Site 101) | Orange | California | 92868 | Recruiting |
| UCLA Medical Center (Site 117) | Santa Monica | California | 90404 | Not yet recruiting |
| Moffitt Cancer Center Magnolia Campus (Site 123) | Tampa | Florida | 33612 | Recruiting |
| City of Hope - Chicago Cancer Center (Site 128) | Zion | Illinois | 60099 | Recruiting |
| Norton Cancer Institute (Site 115) | Louisville | Kentucky | 40127 | Recruiting |
| Ochsner Medical Center (Site 120) | New Orleans | Louisiana | 70121 | Recruiting |
| Karmanos Cancer Center (Site 109) | Detroit | Michigan | 48201 | Recruiting |
| Masonic Cancer Center, University of Minnesota (Site 116) | Minneapolis | Minnesota | 55455 | Recruiting |
| Comprehensive Cancer Centers of Nevada - Central Valley (Site 124) | Las Vegas | Nevada | 89169 | Recruiting |
| Rutgers Cancer Institute of New Jersey (Site 103) | New Brunswick | New Jersey | 08901 | Recruiting |
| Rosewell Park Comprehensive Cancer Center (Site 114) | Buffalo | New York | 14263 | Recruiting |
| Memorial Sloan Kettering Cancer Center (Site 108) | New York | New York | 10065 | Recruiting |
| University Hospitals Cleveland Medical Center Seidman Cancer Center (Site 111) | Cleveland | Ohio | 44106 | Recruiting |
| James Cancer Hospital and Solove Research Institute (Site 119) | Columbus | Ohio | 43219 | Recruiting |
| Mercy Clinic (Site 110) | Oklahoma City | Oklahoma | 73120 | Recruiting |
| University of Texas Southwestern Medical Center (Site 104) | Dallas | Texas | 75390 | Recruiting |
| Fred Hutchinson Cancer Center Clinic (Site 122) | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07265674, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07265674 live on ClinicalTrials.gov.